ArticleFrontiers in pharmacology2025
Preventive effect of small molecule active substances on septic cardiomyopathy after abdominal trauma: a systematic review and meta-analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and meta-analysis aimed to comprehensively evaluate the preventive effects and mechanisms of active small molecules against septic cardiomyopathy (SCM) induced by abdominal trauma or abdominal-origin sepsis in animal models. Methods: The PubMed, Embase, Web of Science, Scopus and Cochrane Library databases were searched in January 2000- May 2025 for studies assessing active small molecules in animal SCM models. The standardised mean difference ([SMD], Hedges' g) with 95% confidence intervals (CIs) was calculated using random-effects meta-analysis. Subgroup analyses were conducted according to molecular categories, sepsis induction methods, and outcome measures. Methodological quality was assessed using the Systematic Review of Laboratory Animal Experiments risk-of-bias tool. Results: Seventeen studies met the inclusion criteria. The pooled meta-analysis showed that active small molecules had an overall beneficial but heterogeneous effect on SCM (SMD = 1.47, 95% confidence interval [CI]: -0.52-3.47, I Conclusion: Active small molecules demonstrate generally positive yet heterogeneous preventive efficacy against SCM in animal models, with polyphenolic compounds in particular showing notable potential. Variability across molecular categories, sepsis models and measured outcomes highlights the need for standardised methodologies in future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.